Technical Analysis for NERV - Minerva Neurosciences, Inc

Grade Last Price % Change Price Change
grade F 3.92 -7.98% -0.34
NERV closed down 7.98 percent on Friday, June 5, 2020, on 2.74 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Very Strong Down Down Down
Historical NERV trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Calm After Storm Range Contraction -7.98%
Wide Bands Range Expansion -7.98%
Oversold Stochastic Weakness -7.98%
Calm After Storm Range Contraction -0.25%
Narrow Range Bar Range Contraction -0.25%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Minerva Neurosciences, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. Its lead product candidates that have completed Phase IIa trials comprise MIN-101, an antagonist on 5-HT2A and sigma2 receptors for the treatment of patients with schizophrenia; and MIN-117, an antagonist on the 5-HT1A receptor, and inhibitor of serotonin and dopamine reuptake for the treatment of major depressive disorder. It is also developing MIN-202, a selective orexin 2 receptor antagonist that is in Phase Ib trials for the treatment of primary and secondary insomnia; and MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein, which is in investigational new drug-enabling studies for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of MIN-202. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences Inc. in 2013. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Drugs Parkinson's Disease Schizophrenia Psychoactive Drugs Neurochemistry Treatment Of Parkinson's Disease Major Depressive Disorder Ketones Antidepressants Central Nervous System Diseases Treatment Of Major Depressive Disorder Treatment Of Central Nervous System Diseases

Is NERV a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 15.215
52 Week Low 1.81
Average Volume 3,256,354
200-Day Moving Average 7.18
50-Day Moving Average 8.51
20-Day Moving Average 10.41
10-Day Moving Average 8.06
Average True Range 1.44
ADX 55.8
+DI 17.41
-DI 45.91
Chandelier Exit (Long, 3 ATRs ) 10.89
Chandelier Exit (Short, 3 ATRs ) 6.13
Upper Bollinger Band 18.98
Lower Bollinger Band 1.85
Percent B (%b) 0.12
BandWidth 164.46
MACD Line -1.40
MACD Signal Line -0.16
MACD Histogram -1.2431
Fundamentals Value
Market Cap 166.64 Million
Num Shares 42.5 Million
EPS -1.08
Price-to-Earnings (P/E) Ratio -3.63
Price-to-Sales 0.00
Price-to-Book 2.36
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.66
Resistance 3 (R3) 4.73 4.57 4.53
Resistance 2 (R2) 4.57 4.38 4.53 4.49
Resistance 1 (R1) 4.24 4.26 4.16 4.17 4.45
Pivot Point 4.08 4.08 4.04 4.04 4.08
Support 1 (S1) 3.75 3.89 3.67 3.68 3.39
Support 2 (S2) 3.59 3.77 3.55 3.35
Support 3 (S3) 3.26 3.59 3.31
Support 4 (S4) 3.19